冠科美博(Apollomics)Uproleselan 注射液(APL-106)用於治療復發或難治性急性髓系白血病的中國 III 期臨床試驗第一例受試者成功入組 Apollomics, Inc. Nov 22, 2021 10:41 HKT/SGT Read More
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia Apollomics, Inc. Nov 22, 2021 10:40 HKT/SGT Read More
휴머니젠, 급성 이식편대 숙주병을 대상으로 렌질루맙의 효과 평가를 위한 임상 연구 협력 발표 Humanigen, Inc. Nov 22, 2021 10:00 HKT/SGT Read More
エーザイ、社会的責任投資指数「Dow Jones Sustainability Asia Pacific Index」に8回目の選定 Eisai Nov 19, 2021 12:00 JST Read More
Aohua Endoscopy, a Leading Endoscope Company Invested by Legend Capital, Successfully Listed on China's STAR Market Legend Capital Nov 15, 2021 17:15 HKT/SGT Read More
Eisai: New Phase 3 Data Show Positive Correlation Between ADUHELM Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer's Disease Eisai Nov 12, 2021 15:10 HKT/SGT Read More
Eisai Presents New Analysis of Lecanemab Clinical Efficacy Results from Phase 2b Study at Clinical Trials On Alzheimer's Disease (CTAD) Conference Eisai Nov 12, 2021 14:31 HKT/SGT Read More
Eisai: Introduction of Plasma-based Biomarker Screening to Facilitate Identification of Subjects for Phase 3 Ahead 3-45 Trial Presented at Clinical Trials on Alzheimer's Disease (CTAD) Conference Eisai Nov 12, 2021 14:03 HKT/SGT Read More
エーザイとバイオジェン、レカネマブの臨床第III相試験の対象者を同定する、初めての血漿中バイオマーカーによる被験者スクリーニングの導入について第14回アルツハイマー病臨床試験会議にて発表 Eisai Nov 12, 2021 12:00 JST Read More
エーザイとバイオジェン、レカネマブの臨床第IIb相試験の臨床効果に関する新たな解析結果を第14回アルツハイマー病臨床試験会議にて発表 Eisai Nov 12, 2021 12:00 JST Read More
バイオジェンとエーザイ、ADUHELMの臨床第III相試験におけるアルツハイマー病の臨床症状の悪化抑制とバイオマーカーとの正の相関を示す新しいデータを第14回アルツハイマー病臨床試験会議にて発表 Eisai Nov 12, 2021 12:00 JST Read More
Olympus Launches Venture Capital Fund to Strengthen Medtech Leadership Olympus Nov 12, 2021 07:30 HKT/SGT Read More
Q&M Dental net profit surges 154% to S$35.4M for nine months ended 30 September 2021 Q&M Dental Group Ltd Nov 11, 2021 14:00 HKT/SGT Read More
エーザイ、レカネマブの臨床第IIb相201試験のコアならびにOLE試験より5年間にわたる臨床バイオマーカーと安全性データに関する最新の知見を第14回アルツハイマー病臨床試験(CTAD)会議において発表 Eisai Nov 11, 2021 13:00 JST Read More
Eisai Presents Late-Breaker Updates on Lecanemab Clinical, Biomarker and Safety Data from Phase 2b Study Core and Open-Label Extension Eisai Nov 11, 2021 11:05 HKT/SGT Read More